1. A phase II study of Guadecitabine (G) with Irinotecan (IRI) vs regorafenib or TAS-102 in metastatic colorectal cancer (mCRC) patients (pts). (October 2020) Authors: Lee, V.; Zahurak, M.; Cercek, A.; Verheul, H.; Lenz, H.; Jones, P.; Baylin, S.; Parkinson, R.; Rami, V.; Lilly, E.; Miles, T.; Brown, T.; Ahuja, N.; El Khoueiry, A.; Azad, N. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. The future for follow-up of gynaecological cancer in Europe. Summary of available data and overview of ongoing trials. (March 2017) Authors: Leeson, S.C.; Beaver, K.; Ezendam, N.P.M.; Mačuks, R.; Martin-Hirsch, P.L.; Miles, T.; Jeppesen, M.M.; Jensen, P.T.; Zola, P. Journal: European journal of obstetrics, gynecology, and reproductive biology Issue: Volume 210(2017) Page Start: 376 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗